🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the fight against superbug strains of the bacteria, according to health experts.

An International Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with data suggesting over 82 million infections per year. Notably increased rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the context of growing infection rates, escalating drug resistance and the highly restricted therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, alternatively called Nuzolvence, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Researchers anticipate that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Data and Worldwide Availability

Based on data released by a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which combines a dual-drug approach. The trial involved over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Doctors treating patients have shared positive views. Access to a single-dose, oral treatment such as this is hailed as a "game-changer" for public health efforts. This is viewed as crucial to reduce the burden of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.